EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events

Ana Camacho-Carrasco, Jorge Montenegro-Martínez, María Luisa Miranda-Guisado, Rocío Muñoz-Hernández iD, Rocío Salsoso iD, Daniel Fatela-Cantillo iD, Lutgardo García-Díaz, Pablo Stiefel García-Junco, Alfonso Mate iD, Carmen M Vázquez iD, Verónica Alfaro-Lara, Antonio J Vallejo-Vaz iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26146684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ana Camacho-Carrasco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Infanta Elena Hospital, 21080 Huelva, Spain. Hauptthemen laut MEDLINE: Pre-Eclampsia, Biomarkers, Pregnancy Trimester, First. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejería de Salud, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the association between known (PlGF, sFlt-1, betaHCG, PAPPA) and novel (cell-free DNA, cfDNA, and total endothelial and platelet microvesicles, MVs) maternal blood biomarkers measured at the first trimester with the later development of preeclampsia (PE) and PE-related severe adverse events (SAE), we conducted a retrospective case–control study including women with an established diagnosis of preeclampsia (cases) and healthy pregnant women (controls). Biomarkers were measured from first-trimester blood samples stored in a hospital biobank. A total of 89 women, 54 women with PE and 35 controls were included. PlGF showed good performance for diagnosing overall preeclampsia (AUC: 0.71; 95% CI 0.59–0.82), early-onset preeclampsia (AUC 0.80; 95% CI 0.68–0.9) and fetal-neonatal SAEs (AUC: 0.73; 95% CI 0.63–0.84). Multivariate models including clinical variables, PlGF and other biomarkers showed good to very good discrimination for the development of PE, early-onset PE and fetal-neonatal SAEs (AUCs of 0.87, 0.89 and 0.79, respectively). Platelet-derived MVs were the best isolated biomarker for late-onset PE and, combined with systolic blood pressure, showed good discrimination (AUC: 0.81; 95% CI 0.71–0.92). For maternal SAEs, a model incorporating cfDNA and sFlt-1 provided excellent discrimination (AUC 0.92; 95% CI 0.82–1.00). Our findings suggest that multivariate models incorporating both clinical variables and first-trimester biomarkers may improve risk stratification for PE, especially for late-onset PE and for identifying women at risk of severe maternal or fetal complications. Notably, the inclusion of novel biomarkers such as cfDNA and MVs added value in clinical scenarios where the predictive performance of existing tools remains suboptimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaBiomarkersPregnancy Trimester, FirstHumansFemalePregnancyAdultCase-Control StudiesRetrospective StudiesVascular Endothelial Growth Factor Receptor-1Placenta Growth FactorCell-Free Nucleic Acids

Stichwörter der Autor:innen

PlGFbiomarkerscell-free nucleic acidsearly-onset preeclampsialate-onset preeclampsiamicrovesiclespreeclampsiasFlt-1screening for pregnancy endpoints

Substanzen

BiomarkersVascular Endothelial Growth Factor Receptor-1Placenta Growth FactorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Internal Medicine, Infanta Elena Hospital, 21080 Huelva, Spain.
  • Department of Clinical Biochemistry, Virgen del Rocío University Hospital, 41013 Sevilla, Spain.
  • Internal Medicine, Virgen del Rocío University Hospital, 41013 Seville, Spain.
  • Clinical Epidemiology and Vascular Risk, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
  • Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, 41009 Sevilla, Spain.
  • Investigación Clínica y Traslacional en Enfermedades Hepáticas y Digestivas-SeLiver, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain.

ORCID-Profile: Rocío Muñoz-Hernández, Rocío Salsoso, Daniel Fatela-Cantillo, Alfonso Mate, Carmen M Vázquez, Antonio J Vallejo-Vaz, Luis M Beltrán-Romero

Förderung

  • Consejería de Salud, Junta de Andalucía

Zitieren

APA

Camacho-Carrasco, A., Montenegro-Martínez, J., Miranda-Guisado, M. L., Muñoz-Hernández, R., Salsoso, R., Fatela-Cantillo, D., García-Díaz, L., Stiefel García-Junco, P., Mate, A., Vázquez, C. M., Alfaro-Lara, V., Vallejo-Vaz, A. J., & Beltrán-Romero, L. M. (2025). Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146684

Vancouver

Camacho-Carrasco A, Montenegro-Martínez J, Miranda-Guisado ML, Muñoz-Hernández R, Salsoso R, Fatela-Cantillo D, et al. Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146684

BibTeX
@article{CamachoCarrasco2025,
  author = {Camacho-Carrasco, Ana and Montenegro-Martínez, Jorge and Miranda-Guisado, María Luisa and Muñoz-Hernández, Rocío and Salsoso, Rocío and Fatela-Cantillo, Daniel and García-Díaz, Lutgardo and Stiefel García-Junco, Pablo and Mate, Alfonso and Vázquez, Carmen M and Alfaro-Lara, Verónica and Vallejo-Vaz, Antonio J and Beltrán-Romero, Luis M},
  title = {Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26146684}
}
Kostenlos starten →